Students of the Internship program of the Ministry of Industry and Trade of the Russian Federation Russia intended for the formation of a Youth personnel reserve got acquainted with the organization of the work of the scientific departments of the FSUE Endopharm, visiting the scientific lab building opened this spring in the Lefortovsky branch with an area of about 7,000 m².
At the opening of the scientific lab building on March 22, 2023, Vasily Osmakov, the First Deputy Minister of Industry and Trade of the Russian Federation, stressed that the commissioning of this facility is a significant step towards ensuring the technological sovereignty of the country in drugs production.
“The opening of a modern R&D complex is one of the stages of a large-scale investment project for the re-equipment of production, which is being implemented with the support of the Ministry of Industry and Trade of the Russian Federation. Its result will be the creation of a powerful industrial complex with a state-of-the-art research and laboratory base,” commented the first deputy head of the Ministry of Industry and Trade of the Russian Federation.
Students of the Internship program of the Ministry of Industry and Trade of the Russian Federation noted the high-tech equipment of the scientific lab building in the Lefortovsky branch. Indeed, the total investment in the construction and equipment of this building amounted to 944 million rubles. The participants were particularly interested in the positive feedback from the employees of the scientific departments of the FSUE Endopharm regarding the work of domestic analytical equipment for conducting research using gas chromatography and capillary electrophoresis.
The students visited the production facility for active pharmaceutical substances, the pilot production facility for drugs, the facility for the development and production of reference standards, as well as analytical labs and laboratories for the development and transfer of advanced technologies for the production of finished drug products. The students got an idea of the main scientific, technological and economic aspects of pharmaceutical developments.
Taking into account that more than 75% of the product range is included in the VED list, the main task of the FSUE Endopharm is to ensure the uninterrupted availability of the entire line of manufactured drugs for citizens of the country who need them for medical reasons, including in conditions of unpredictable international market relations.
The scientific divisions of the Enterprise, located in the Lefortovsky branch, play a key role in the organization of import-independent production of full-cycle drugs in demand by the domestic healthcare system, ensuring the development of technologies for the production of their own active pharmaceutical substances, the development and production of reference standards, and the implementation of innovative developments of finished dosage forms.
Over the previous 5 years, the FSUE Endopharm has increased its investment in R&D by 12 times, which allowed the Enterprise to increase competence in the development and production of new drugs, shorten the time frame of research and reduce the dependence on imports.
“Now the FSUE Endopharm is producing 124 reference standards and 12 active pharmaceutical substances. Another 4 active pharmaceutical substances are undergoing the registration procedure and are going to be included in the regulatory documentation for drugs to ensure their full cycle production,” said Alfiya Gabidova, the First Deputy Director General for Science of the FSUE Endopharm.
By 2027, the Enterprise plans to introduce at least 65 domestic active pharmaceutical substances obtained by chemical and biotechnological synthesis from plant and animal raw materials, as well as more than 80 new medicines in demand for palliative care, treatment of ophthalmic diseases, in psychiatry and neurology, anticoagulants, anti-tumor agents, etc.
In 2026, the Lefortovsky branch will organize a facility with an area of about 14,000 m² for the production of finished dosage forms.
Comment type is not specified in the component properties.